Arcoma AB (ARCOMA.ST)
SEK 10.95
(3.3%)
SEK 10.95
(3.3%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 4.66 Million SEK | 141.6% |
| 2022 | 3.12 Million SEK | 141.94% |
| 2021 | -7.45 Million SEK | -425.84% |
| 2020 | 2.28 Million SEK | -74.87% |
| 2019 | 9.09 Million SEK | 2475.72% |
| 2018 | -383 Thousand SEK | 96.17% |
| 2017 | -9.99 Million SEK | 22.42% |
| 2016 | -12.87 Million SEK | -107.79% |
| 2015 | -6.19 Million SEK | -1177.91% |
| 2014 | 575 Thousand SEK | 105.8% |
| 2013 | -9.9 Million SEK | -1577.68% |
| 2012 | -590.66 Thousand SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 3.36 Million SEK | -24.39% |
| 2024 Q3 | 2.41 Million SEK | -28.25% |
| 2024 Q1 | 4.44 Million SEK | -4.08% |
| 2023 Q3 | 2.31 Million SEK | 243.03% |
| 2023 Q1 | -1.89 Million SEK | -354.29% |
| 2023 FY | 7.55 Million SEK | 141.6% |
| 2023 Q4 | 4.63 Million SEK | 100.56% |
| 2023 Q2 | 674 Thousand SEK | 135.53% |
| 2022 Q1 | -967 Thousand SEK | 89.18% |
| 2022 FY | 3.12 Million SEK | 141.94% |
| 2022 Q4 | 746 Thousand SEK | -52.78% |
| 2022 Q2 | 1.82 Million SEK | 288.21% |
| 2022 Q3 | 1.58 Million SEK | -13.19% |
| 2021 Q1 | 1.85 Million SEK | 142.72% |
| 2021 Q4 | -8.93 Million SEK | -215.13% |
| 2021 Q2 | 1.12 Million SEK | -39.34% |
| 2021 Q3 | -2.83 Million SEK | -352.22% |
| 2021 FY | -7.45 Million SEK | -425.84% |
| 2020 Q2 | 2.26 Million SEK | -46.32% |
| 2020 Q1 | 4.21 Million SEK | 24.71% |
| 2020 Q3 | 1.36 Million SEK | -39.48% |
| 2020 Q4 | -4.33 Million SEK | -416.87% |
| 2020 FY | 2.28 Million SEK | -74.87% |
| 2019 Q2 | 2.48 Million SEK | 202.81% |
| 2019 Q4 | 3.37 Million SEK | 39.57% |
| 2019 Q3 | 2.42 Million SEK | -2.38% |
| 2019 Q1 | 819 Thousand SEK | 174.83% |
| 2019 FY | 9.09 Million SEK | 2475.72% |
| 2018 Q4 | 298 Thousand SEK | 75.29% |
| 2018 FY | -383 Thousand SEK | 96.17% |
| 2018 Q3 | 170 Thousand SEK | -78.09% |
| 2018 Q2 | 776 Thousand SEK | 147.7% |
| 2018 Q1 | -1.62 Million SEK | -73.27% |
| 2017 Q1 | -1.67 Million SEK | -551.36% |
| 2017 FY | -9.99 Million SEK | 22.42% |
| 2017 Q4 | -939 Thousand SEK | 79.57% |
| 2017 Q3 | -4.59 Million SEK | -65.3% |
| 2017 Q2 | -2.78 Million SEK | -66.13% |
| 2016 FY | -12.87 Million SEK | -107.79% |
| 2016 Q4 | -257 Thousand SEK | 76.34% |
| 2016 Q3 | -1.08 Million SEK | 78.59% |
| 2016 Q2 | -5.07 Million SEK | 21.35% |
| 2016 Q1 | -6.45 Million SEK | -8062.96% |
| 2015 Q1 | 1.84 Million SEK | 197.36% |
| 2015 Q2 | -6.44 Million SEK | -449.32% |
| 2015 Q3 | -1.67 Million SEK | 73.95% |
| 2015 FY | -6.19 Million SEK | -1177.91% |
| 2015 Q4 | 81 Thousand SEK | 104.82% |
| 2014 Q1 | 1.16 Million SEK | 130.96% |
| 2014 Q2 | 1.61 Million SEK | 38.78% |
| 2014 Q3 | -278 Thousand SEK | -117.22% |
| 2014 Q4 | -1.89 Million SEK | -581.65% |
| 2014 FY | 575 Thousand SEK | 105.8% |
| 2013 Q3 | -1.42 Million SEK | 0.0% |
| 2013 FY | -9.9 Million SEK | -1577.68% |
| 2013 Q4 | -3.75 Million SEK | -163.42% |
| 2012 FY | -590.66 Thousand SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Acarix AB (publ) | -77.55 Million SEK | 106.009% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 98.45% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 98.45% |
| Bactiguard Holding AB (publ) | -131.93 Million SEK | 103.532% |
| BICO Group AB (publ) | -618.3 Million SEK | 100.754% |
| Boule Diagnostics AB (publ) | 39.27 Million SEK | 88.133% |
| CellaVision AB (publ) | 167.05 Million SEK | 97.21% |
| Clinical Laserthermia Systems AB (publ) | -65.93 Million SEK | 107.068% |
| Chordate Medical Holding AB (publ) | -29.57 Million SEK | 115.758% |
| C-Rad AB (publ) | 44.24 Million SEK | 89.467% |
| Duearity AB (publ) | -25.76 Million SEK | 118.088% |
| Dignitana AB (publ) | -15.02 Million SEK | 131.013% |
| Episurf Medical AB (publ) | -94.8 Million SEK | 104.916% |
| Getinge AB (publ) | 3.81 Billion SEK | 99.878% |
| Scandinavian Real Heart AB (Publ) | -68.44 Million SEK | 106.808% |
| Iconovo AB (publ) | -45.77 Million SEK | 110.18% |
| Integrum AB (publ) | 6.51 Million SEK | 28.444% |
| Luxbright AB (publ) | -25.8 Million SEK | 118.059% |
| Mentice AB (publ) | -679 Thousand SEK | 786.303% |
| OssDsign AB (publ) | -91.95 Million SEK | 105.068% |
| Paxman AB (publ) | 12.61 Million SEK | 63.072% |
| Promimic AB (publ) | -9.11 Million SEK | 151.108% |
| Qlife Holding AB (publ) | -168.69 Million SEK | 102.762% |
| SciBase Holding AB (publ) | -53.93 Million SEK | 108.639% |
| ScandiDos AB (publ) | -13.48 Million SEK | 134.562% |
| Sectra AB (publ) | 518.49 Million SEK | 99.101% |
| Sedana Medical AB (publ) | -65.54 Million SEK | 107.109% |
| Senzime AB (publ) | -133.74 Million SEK | 103.484% |
| SpectraCure AB (publ) | -21.35 Million SEK | 121.826% |
| Stille AB | 44.95 Million SEK | 89.633% |
| Vitrolife AB (publ) | -3.58 Billion SEK | 100.13% |
| Xvivo Perfusion AB (publ) | 38.5 Million SEK | 87.898% |